Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1644-1650

  Sano, Keita ^a   Nakamura, Takamitsu ^a   Hirano, Mitsumasa ^a   Kitta, Yoshinobu ^a   Kobayashi, Tsuyoshi ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Yano, Toshiaki ^a   Watanabe, Kazuhiro ^a   Watanabe, Yosuke ^a   Mishina, Hideto ^a   Obata, Jyun ei ^a   Kawabata, Ken ichi ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Cardiovascular disease; Fibrates; Remnant lipoprotein; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LIPOPROTEIN; PRAVASTATIN; SULFONYLUREA; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; FOLLOW UP; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; RISK REDUCTION;

AGED; ANTICHOLESTEREMIC AGENTS; BEZAFIBRATE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PRAVASTATIN; TRIGLYCERIDES;

EID: 77955077692     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0079     Document Type: Article

References (28)

1. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88: 2762-2770.
2. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mid/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42-49.
3. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18B-25B.
4. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: Results from the Framingham Heart Study. Atherosclerosis 2001; 154: 229-236.
5. Boquist S, Ruotolo G, Tang R, Björkegren J, Bond MG, de Faire U, et al. Alimentary lipemia, postprandial triglyceride-rich lipo-proteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999; 100: 723-728.
6. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998; 97: 2519-2526.
7. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-2860.
8. Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181: 321-327.
9. Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000; 102: 670-676.
10. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffnity mixed gels. Clin Chim Acta 1993; 223: 53-71.
11. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoprotein isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33: 369-380.
12. Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T, et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 2004; 43: 2219-2224.
13. Ooi TC, Cousins M, Ooi DS, Nakajima K, Edwards AL. Effect of fbrates on postprandial remnant-like particles in patients with combined hyperlipidemia. Atherosclerosis 2004; 172: 375-382.
14. Nagai T, Tomizawa T, Nakajima K, Mori M. Effect of bezafbrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 2000; 7: 91-96.
15. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, et al. Comparisons of effects of statins (atorvastatin, fuvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004; 93: 31-39.
16. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafbrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-1160.
17. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Infuence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-3051.
18. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724-730.
19. Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, et al; Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002; 9: 1-27.
20. Stein DT, Devaraj S, Balis D, Adams-Huet B, Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001; 21: 2026-2031.
21. Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafbrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2005; 59: 181-189.
22. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
23. Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S, et al. Effects of pitavastatin on fasting and postprandial endothelial function and blood Rheology in patients with stable coronary artery disease. Circ J 2009; 73: 1523-1530.
24. Twickler TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration: A characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004; 109: 1918-1925.
25. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fbrates on lipid and lipopro-tein metabolism. Circulation 1998; 98: 2088-2093.
26. Civeira F, Cenarro A, Ferrando J, Puzo J, Garcia-Otín AL, Mozas P, et al. Comparison of the hypolipidemic effect of gemfbrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J 1999; 138: 156-162.
27. Secondary prevention by raising HDL cholesterol and reducing tri-glycerides in patients with coronary artery disease: The Bezafbrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.
28. Ishikawa T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, et al; MEGA Study Group. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circ J 2008; 72: 1576-1582.